



INTERMACS Ninth Annual Meeting
MCSDs in 2015: Evolution, Expansion, and Evaluation
May 15-16, 2015

Room: Salons 1 and 2

Friday May 15, 2015

5:30 pm Registration

6:00 pm Dinner

6:30 pm Session 1: MCS In Special Populations

- Chemotherapy (Adriamycin)
- HIV
- The Use of Mechanical Support in Adults with Congenital Heart Disease
- Peri Partum
- Restrictive and Obstructive Cardiomyopathies
- Acute Myocardial Infarction
- Who Should Not Receive a VAD: Pragmatism and Futility in Patient Selection

Frank Pagani, MD, PhD
Guilherme Oliveira, MD
Salpy Pamboukian, MD, MSPH
Christina VanderPluym, MD

Renzo Loyaga-Rendon, MD, PhD
John Stulak, MD
Deepak Acharya, MD
Joseph Rogers, MD



INTERMACS Ninth Annual Meeting
MCSDs in 2015: Evolution, Expansion, and Evaluation
May 15-16, 2015

Room: Salons 1 and 2

Saturday May 16, 2015

7:00 am Registration

7:30 am Session 2: INTERMACS Overview / Update

- Enrollment
- 4.0 Update / Relaunch / Waiver of Consent / WBDE

James K. Kirklin, MD
David C. Naftel, PhD

7:40 am Session 3: Patterns of MCS Utilization

- Impact of MCS Complications on Transplant Status
- Temporary Devices as a Bridge to More Permanent MCS
- RVAD Utilization

James Young, MD
Todd Dardas, MD, MS
Eduardo Rame, MD, MPhil, MS

Michael Kiernan, MD, MS

8:30 am Session 4: Pediatric Device Issues

- First 100 Patients (or 200 Patients)
- Impact of MCS Therapy on Pediatric Transplantation

David Rosenthal, MD
Elizabeth Blume, MD
Chris Almond, MD

9:00 am Session 5: New Pump Updates

- MVAD / Circulite Update
- HeartMate III Update
- SynCardia 50mL

Robert Kormos, MD
Katrin Leadley, MD
David Farrar, PhD
Francisco Arabia, MD, MBA

9:45 am Break

10:15 am Session 6: Quality of Life

- Quantifying the Impact of Adverse Events on Health-related Quality of Life Early after Implant
- Patient Selection and Estimation of Prognosis after LVAD Implant: Use of Health Status Measures
- Predicting Patients at Risk for Poor Global

Kathy Grady, PhD, APN
Kathy Grady, PhD, APN

Kelsey Flint, MD

Suzanne Arnold, MD

Outcomes after DT MCS Therapy

- 11:00 am Session 7: New Surgical Strategies**
- Non-sternotomy Surgical Approaches for Implantation of Continuous Flow VADS
 - Size Limitations for Current Continuous Flow Pumps: How young can we go?
- James Kirklin, MD**
Simon Maltais, MD, PhD
- Iki Adachi, MD**
- 11:30 am Session 8: Hospital / Quality Assurance / Joint Commission**
- Using QA Data to Guide a Successful VAD Program
 - Joint Commission View on MCS QA
 - Hospital Challenges in MCS Utilization
- Robert Kormos, MD**
- Barbara A. Elias, RN, CCRN**
Tonya Elliott, PHR
Pavan Atluri, MD
- 12:15 pm Lunch & Awards Ceremony**
- 1:15 pm Session 9: Pump Thrombosis Update**
- Anticoagulation: Review of Best Practices
 - Continuous Flow Pump Thrombosis Update
- James Kirklin, MD**
Salpy Pamboukian, MD, MSPH
James Kirklin, MD
- 1:45 pm Session 10: Decision Making Challenges**
- Presenting Choices to Patients
 - The Roadmap for Medical Patients
 - Medamacs: Who Gets to the End of Medical Therapy
 - Are BTT / DT Designations Still Relevant to VAD Outcomes
 - Panel Discussion: Projecting Outcomes for Ambulatory Patients without VAD
 - INTERMACS Risk Model for MCS Outcomes in Ambulatory Profiles 4-6
 - Questions
- Lynne Warner Stevenson, MD**
Larry Allen, MD, MHS
Joseph Rogers, MD
Garrick Stewart, MD, MPH
- Josef Stehlik, MD, MPH**
- Joseph Rogers, MD; Josef Stehlik, MD, MPH; Larry Allen, MD, MHS; MedaMACS Representative**
James Kirklin, MD
David Naftel, PhD
- 3:00 pm Adjourn**